Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25637694 | 0.88 | ALDH1A1 (0.38) | SIRT6LMNAALDH1A1SMN1; SMN2PKM | |
| SCHEMBL25637845 | 0.86 | SMN1; SMN2 (0.32) | SIRT6LMNAALDH1A1SMN1; SMN2POLB | |
| SCHEMBL25637762 | 0.85 | HTR2A (0.38) | SIRT6LMNAALDH1A1SMN1; SMN2HTT | |
| SCHEMBL25637647 | 0.84 | SIRT6 (0.39) | SIRT6LMNAALDH1A1SMN1; SMN2PKM | |
| SCHEMBL25640764 | 0.84 | SIK2 (0.35) | SIRT6LMNAALDH1A1SMN1; SMN2PKM | |
| SCHEMBL25637849 | 0.84 | SIRT6 (0.38) | SIRT6LMNAALDH1A1SMN1; SMN2PKM | |
| SCHEMBL25056317 | 0.84 | CYP11B1 (0.33) | — | |
| SCHEMBL25637772 | 0.82 | SIRT6 (0.38) | SIRT6LMNAALDH1A1PKMKMT2A | |
| SCHEMBL25637666 | 0.81 | TDP1 (0.40) | SIRT6LMNAALDH1A1SMN1; SMN2PKM | |
| SCHEMBL25056275 | 0.81 | S1PR1 (0.35) | SIRT6LMNAALDH1A1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | SIRT6 4278/4885LMNA 2845/4885ALDH1A1 3656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.